Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of SSS67 in Healthy Adult Participants Via Single Intravenous Infusion

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of SSS67 in Healthy Adult Participants Via Single Intravenous Infusion

This is a randomized, double-blind, placebo-controlled, single ascending dose phase I clinical study to evaluate the safety, tolerability, PK, preliminary PD and immunogenicity of SSS67 in healthy adult participants after single intravenous infusion.

The primary objective is to assess the safety and tolerability of SSS67 following single ascending doses.

The secondary objectives are to characterize the PK, PD, and anti-drug antibody (ADA) profiles of SSS67 after single administration.

The exploratory objective is to evaluate changes in body weight, waist circumference, and other related metabolic parameters following a single dose of SSS67.

Study Overview

• Status: Not yet recruiting
• Conditions: Healthy
• Intervention / Treatment: Drug: SSS67 Injection; Drug: Placebo

• Study Type: Interventional
• Enrollment (Estimated): 52
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Xiujuan Liu; Phone Number: +86 15942305899; Email: liuxiujuan1@3sbio.com

Study Locations

• Australia
  • New South Wales
    • Charlestown, New South Wales, Australia, 2290
      • Novatrials
      • Contact: Director Clinical; Phone Number: +61 240893746; Email: toni@novatrials.com.au
• China
  • Hebei
    • Shijiazhuang, Hebei, China
      • The First Hospital of Hebei Medical University
      • Contact: Chunhua Zhou; Phone Number: +86 18633881377; Email: zhouchunhua80@126.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Participants aged 18 to 65 years (inclusive), regardless of gender.
• Participate in the clinical trial voluntarily and provide informed consent form.
• At screening, body weight ≥ 50 kg for males and ≥ 45 kg for females. Body Mass Index (BMI) must be between 18.5 and 32 kg/m² (inclusive).
• At screening, the following must be within normal ranges or assessed by the investigator as abnormal but not clinically significant: Vital signs、Physical examination、12-lead electrocardiogram (ECG)、Chest X-ray (posteroanterior view) or lung computed tomography (CT)、Ultrasound (abdominal, urological, and gynecological [for females only])、Clinical laboratory tests (including hematology, urinalysis, blood biochemistry, coagulation, serum virolgy and thyroid function).
• Female participants with childbearing potential and male participants (and their female partners) must agree to take highly effective contraceptive measures and have no plan of childbearing, sperm donation, or egg donation from screening through at least 6 months after the last dose of investigational drug.
• Able to understand and comply with protocol requirements.

Exclusion Criteria:

• History of significant drug or food allergies; or known clinically significant hypersensitivity to the study intervention or related compounds.
• History of risk factors for torsades de pointes (e.g., heart failure/cardiomyopathy or family history of long QT syndrome), uncorrected hypokalemia or hypomagnesemia (one retest may be allowed per Investigator's judgment), or QT (QTcF) interval >450 ms.
• Any clinically significant medical condition or illness that could compromise participant safety or interfere with study results.
• History of any malignancy within the past 5 years, except for basal cell carcinoma, squamous cell carcinoma in situ, or cervical carcinoma in situ th with no evidence of metastatic disease for 3 years.
• Known concomitant conditions affecting skeletal muscle, or use of any medications or supplements known to influence muscle anabolism/catabolism within 3 months prior to screening.
• History of gastrointestinal surgery resulting in malabsorption, or chronic use of medications that s directly affect gastrointestinal motility. Examples: history of bariatric surgery/procedures (e.g., gastric banding), use of medications/products deemed by the investigator to cause weight change and affect weight assessment within 3 months prior to dosing, or intention to use weight-loss drugs during the study.
• Use of any prescription drugs or over-the-counter medications, herbal medicines, or dietary supplements within 4 weeks prior to screening (participants may be enrolled if the investigator confirms the time interval between last use and the first dose in this trial is >5 half-lives of the drug).
• Use of drugs potentially affecting follicle-stimulating hormone (FSH) levels within 90 days prior to screening, or planned use during the study.
• Regular weightlifting, bodybuilding, or strength training aimed at increasing muscle mass.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

6

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: SSS67 1mg/kg; This is a single-dose group. 2 participants will be enrolled and receive a single intravenous infusion of SSS67 at 1 mg/kg on Day 1. No placebo is administered in this group.	Drug: SSS67 Injection; In this Phase 1 single ascending dose trial, SSS67 Injection will be administered via intravenous infusion.
Experimental: SSS67 5mg/kg+Placebo; This is a single-dose group. 10 participants will be enrolled: 8 receive a single intravenous infusion of SSS67 at 5 mg/kg on Day 1, and 2 receive matching placebo on Day 1.	Drug: SSS67 Injection; In this Phase 1 single ascending dose trial, SSS67 Injection will be administered via intravenous infusion.; Drug: Placebo; Participants will receive a single dose of matching placebo in accordance with their randomly assigned treatment group.
Experimental: SSS67 15mg/kg+Placebo; This is a single-dose group. 10 participants will be enrolled: 8 receive a single intravenous infusion of SSS67 at 15 mg/kg on Day 1, and 2 receive matching placebo on Day 1.	Drug: SSS67 Injection; In this Phase 1 single ascending dose trial, SSS67 Injection will be administered via intravenous infusion.; Drug: Placebo; Participants will receive a single dose of matching placebo in accordance with their randomly assigned treatment group.
Experimental: SSS67 30mg/kg+Placebo; This is a single-dose group. 10 participants will be enrolled: 8 receive a single intravenous infusion of SSS67 at 30 mg/kg on Day 1, and 2 receive matching placebo on Day 1.	Drug: SSS67 Injection; In this Phase 1 single ascending dose trial, SSS67 Injection will be administered via intravenous infusion.; Drug: Placebo; Participants will receive a single dose of matching placebo in accordance with their randomly assigned treatment group.
Experimental: SSS67 45mg/kg+Placebo; This is a single-dose group. 10 participants will be enrolled: 8 receive a single intravenous infusion of SSS67 at 45 mg/kg on Day 1, and 2 receive matching placebo on Day 1.	Drug: SSS67 Injection; In this Phase 1 single ascending dose trial, SSS67 Injection will be administered via intravenous infusion.; Drug: Placebo; Participants will receive a single dose of matching placebo in accordance with their randomly assigned treatment group.
Experimental: SSS67 60mg/kg+Placebo; This is a single-dose group. 10 participants will be enrolled: 8 receive a single intravenous infusion of SSS67 at 60 mg/kg on Day 1, and 2 receive matching placebo on Day 1.	Drug: SSS67 Injection; In this Phase 1 single ascending dose trial, SSS67 Injection will be administered via intravenous infusion.; Drug: Placebo; Participants will receive a single dose of matching placebo in accordance with their randomly assigned treatment group.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Incidence and severity of AEs	Day 57

Secondary Outcome Measures

Outcome Measure	Time Frame
Peak concentration	Day 57
Incidence of antidrug antibodies (ADAs) to SSS67 over time	Day 57
Bone formation biomarker	Day 57
bone resorption biomarker	Day 57

Collaborators and Investigators

• Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.

Study record dates

Study Major Dates

• Study Start (Estimated): March 31, 2026
• Primary Completion (Estimated): August 29, 2026
• Study Completion (Estimated): April 2, 2027

Study Registration Dates

• First Submitted: March 17, 2026
• First Submitted That Met QC Criteria: March 17, 2026
• First Posted (Actual): March 23, 2026

Study Record Updates

• Last Update Posted (Actual): March 23, 2026
• Last Update Submitted That Met QC Criteria: March 17, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Other Study ID Numbers: SSS67-101

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Due to the nature of the study and privacy concerns, de-identified individual participant data will not be made available to external researchers.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No